{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"38.2","value":"1470"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"Cmax is the maximum serum concentration of asciminib during a dosing interval (mass x volume-1).","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Patients took asciminib 80 mg QD under fasting conditions on ongoing basis.","id":"OG000","title":"Asciminib (All Asciminib)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Full PK samples were collected at Week 2","reportingStatus":"POSTED","timeFrame":"Week 2 (0 hours (h) pre-dose, 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose)","title":"Pharmacokinetics (PK) of Asciminib: Cmax","type":"SECONDARY","unitOfMeasure":"ng/mL"}